This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Proton Radiation Therapy for Spinal Tumors (NF01)

This study has been withdrawn prior to enrollment.
(Feasibility issues)
Information provided by (Responsible Party):
University of Florida Identifier:
First received: March 13, 2012
Last updated: February 9, 2017
Last verified: February 2017
The purpose of this study is to determine if Proton Therapy can provide effective and safe treatment for Malignant Peripheral Nerve Sheath Tumors of the spine and Neurofibromas of the spine.

Condition Intervention
Nerve Sheath Tumors Neurofibroma Radiation: Proton Radiation for MPNST Radiation: Proton Radiation for neurofibromas

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Spinal Tumor Proton Protocol

Resource links provided by NLM:

Further study details as provided by University of Florida:

Primary Outcome Measures:
  • Local Control [ Time Frame: 7 years after completion of RT ]

Secondary Outcome Measures:
  • Progression or palliation of pain, numbness, or weakness [ Time Frame: At 3, 6, 12, 24 and 60 months after RT ]
  • Number of adverse events [ Time Frame: At 3, 6, 12, 24, 60 months and 15 years after RT ]
  • Quality of Life [ Time Frame: 3, 6, 12, 24 and 60 months after RT ]
  • Rate of malignant transformation within the high-dose volume [ Time Frame: 15 years after RT ]
  • Rate of second malignant primaries outside of high dose volume, but located in tissues exposed to radiation within the beam path [ Time Frame: 15 years after RT ]

Enrollment: 0
Study Start Date: June 2013
Study Completion Date: August 2015
Primary Completion Date: August 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Proton Radiation for MPNST
Proton radiation 30 cobalt gray equivalent(CGE)at 6 CGE per fraction
Radiation: Proton Radiation for MPNST
30 CGE at 6 CGE/Fx
Experimental: Proton Radiation for neurofibromas
Proton radiation 25 cobalt gray equivalent(CGE) at 5 CGE per fraction
Radiation: Proton Radiation for neurofibromas
25 CGE at 5 CGE/Fx

Detailed Description:
Proton therapy may provide the benefits of local control or palliation, while reducing the risk associated with photon radiation, by delivering therapeutic doses to a well-defined target area with significant reduction in the integral dose. A dosimetry comparison of protons and photons at the University of Florida Proton Therapy Institute confirmed the feasibility of proton irradiation of these tumors with less exposure of normal tissue to radiation than expected with photon techniques. This reduced radiation exposure to uninvolved normal tissues is expected to decrease the risk of radiation-induced second malignancies and neoplasms.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • MPNSTs that are biopsy-positive and resected, subtotally resected or unresectable.
  • Symptomatic (pain, numbness, or weakness) NF1 neurofibromas that are biopsy-positive and unresectable or subtotally resected.
  • Symptomatic NF1 neurofibromas that are unbiopsied and PET-negative, if the patient refuses biopsy/surgery or is medically inoperable.
  • Asymptomatic NF1 neurofibromas with radiologic progression after surgery.
  • PET-positive, unbiopsied lesions in NF1 patients who refuse biopsy/surgery or are medically inoperable.

Exclusion Criteria:

  • Spinal instability.
  • Metal stabilization hardware within the target area.
  • Previously irradiated at this disease site.
  • Spinal cord compression with complete loss of function.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01567787

Sponsors and Collaborators
University of Florida
Principal Investigator: Randal H Henderson, MD University of Florida Proton Therapy Institute
  More Information

Schadev S, Dodd RL, Chang SD, Soltys SG, Adler JR, Luxton G, Choi CYH, Tupper LA, Gibbs IC. Stereotactic Radiosurgery Yields Long-term Control for Benign Intradural, Extramedullary Spine Tumors. Int J Radiat Oncol Biol Phys 2009; 75:101 (Abstract)

Responsible Party: University of Florida Identifier: NCT01567787     History of Changes
Other Study ID Numbers: UFPTI 1101-NF01
Study First Received: March 13, 2012
Last Updated: February 9, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Florida:
Proton Radiation Therapy
Spinal tumors
Malignant peripheral nerve sheath tumor(MPNST)

Additional relevant MeSH terms:
Nerve Sheath Neoplasms
Spinal Cord Neoplasms
Spinal Neoplasms
Neoplasms, Nerve Tissue
Neoplasms by Histologic Type
Peripheral Nervous System Neoplasms
Nervous System Neoplasms
Nervous System Diseases
Peripheral Nervous System Diseases
Neuromuscular Diseases
Neoplastic Syndromes, Hereditary
Neurocutaneous Syndromes
Heredodegenerative Disorders, Nervous System
Neurodegenerative Diseases
Genetic Diseases, Inborn
Central Nervous System Neoplasms
Neoplasms by Site
Spinal Cord Diseases
Central Nervous System Diseases
Bone Neoplasms
Bone Diseases
Musculoskeletal Diseases
Spinal Diseases processed this record on August 18, 2017